WO2014139476A8 - Rsv融合蛋白的表位以及识别其的抗体 - Google Patents

Rsv融合蛋白的表位以及识别其的抗体 Download PDF

Info

Publication number
WO2014139476A8
WO2014139476A8 PCT/CN2014/073505 CN2014073505W WO2014139476A8 WO 2014139476 A8 WO2014139476 A8 WO 2014139476A8 CN 2014073505 W CN2014073505 W CN 2014073505W WO 2014139476 A8 WO2014139476 A8 WO 2014139476A8
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
antibody
fusion protein
rsv fusion
identifying same
Prior art date
Application number
PCT/CN2014/073505
Other languages
English (en)
French (fr)
Other versions
WO2014139476A1 (zh
Inventor
郑子峥
贾森·S·麦克莱伦
陈曼
赵敏
黄粱敏
巴尼·S·格雷厄姆
夏宁邵
Original Assignee
厦门大学
(由卫生与公众服务部部长代表的)美利坚合众国
厦门万泰沧海生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 厦门大学, (由卫生与公众服务部部长代表的)美利坚合众国, 厦门万泰沧海生物技术有限公司 filed Critical 厦门大学
Priority to AU2014231357A priority Critical patent/AU2014231357B2/en
Priority to CN201480013927.7A priority patent/CN105722856B/zh
Priority to EP14765573.2A priority patent/EP2975052B1/en
Priority to US14/777,275 priority patent/US9856313B2/en
Priority to JP2015561931A priority patent/JP6462599B2/ja
Priority to CA2906960A priority patent/CA2906960C/en
Publication of WO2014139476A1 publication Critical patent/WO2014139476A1/zh
Publication of WO2014139476A8 publication Critical patent/WO2014139476A8/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了可用于预防呼吸道合胞病毒感染的表位肽或其变体和包含该表位肽或其变体与载体蛋白的重组蛋白，以及它们的用途。本发明还提供了针对这些表位肽的抗体和产生所述抗体的细胞株，以及它们的用途。另外，本发明还提供了包含所述重组蛋白的疫苗或包含所述抗体的药物组合物，其可用于预防呼吸道合胞病毒感染相关的症状。
PCT/CN2014/073505 2013-03-15 2014-03-17 Rsv融合蛋白的表位以及识别其的抗体 WO2014139476A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2014231357A AU2014231357B2 (en) 2013-03-15 2014-03-17 Epitope of RSV fusion protein and antibody identifying same
CN201480013927.7A CN105722856B (zh) 2013-03-15 2014-03-17 Rsv融合蛋白的表位以及识别其的抗体
EP14765573.2A EP2975052B1 (en) 2013-03-15 2014-03-17 Epitope of rsv fusion protein and antibody identifying same
US14/777,275 US9856313B2 (en) 2013-03-15 2014-03-17 Epitope of RSV fusion protein and antibody recognizing the same
JP2015561931A JP6462599B2 (ja) 2013-03-15 2014-03-17 Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
CA2906960A CA2906960C (en) 2013-03-15 2014-03-17 Epitope of rsv fusion protein and antibody recognizing the epitope

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310082338 2013-03-15
CN201310082338.1 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014139476A1 WO2014139476A1 (zh) 2014-09-18
WO2014139476A8 true WO2014139476A8 (zh) 2015-06-25

Family

ID=51535878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/073505 WO2014139476A1 (zh) 2013-03-15 2014-03-17 Rsv融合蛋白的表位以及识别其的抗体

Country Status (7)

Country Link
US (1) US9856313B2 (zh)
EP (1) EP2975052B1 (zh)
JP (1) JP6462599B2 (zh)
CN (1) CN105722856B (zh)
AU (1) AU2014231357B2 (zh)
CA (1) CA2906960C (zh)
WO (1) WO2014139476A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
MX2015013065A (es) 2013-03-13 2016-06-06 Us Health Proteinas f de rsv de prefusion y su uso.
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CN106496324B (zh) * 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
ES2858315T3 (es) * 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
IL303833A (en) * 2016-10-21 2023-08-01 Adimab Llc Respiratory syncytial virus antibodies and methods for their production and use
CN110121509B (zh) * 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
EP3554545A4 (en) * 2016-12-19 2020-08-12 Vanderbilt University ANTIBODIES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION PROTEIN CONFORMATION AND THEIR USE METHODS
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
CN108300705B (zh) * 2017-01-12 2021-10-22 厦门大学 稳定呼吸道合胞病毒融合蛋白的方法
MX2019011869A (es) 2017-04-04 2020-01-09 Univ Washington Nanoestructuras proteicas auto-ensamblables que muestran proteinas f de paramixovirus y/o neumovirus y su uso.
US11771755B2 (en) 2018-02-28 2023-10-03 University Of Washington Self-asssembling nanostructure vaccines
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN111057718A (zh) * 2018-10-17 2020-04-24 南京大学 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法
WO2020175660A1 (ja) * 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
WO2021242294A1 (en) * 2020-05-28 2021-12-02 Sotira Covid, Llc Peptides for covid-19 prevention and treatment
WO2022268120A1 (en) * 2021-06-22 2022-12-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-rsv antibodies and uses thereof
CA3235979A1 (en) * 2021-12-06 2023-06-15 Xiamen University Antibody for recognizing rsv pre-f protein and use thereof
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
RU2540020C2 (ru) * 2009-10-06 2015-01-27 Медиммьюн Лтд Молекула, специфически связывающаяся с rsv
US8568726B2 (en) * 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
CN102210860B (zh) * 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法

Also Published As

Publication number Publication date
EP2975052B1 (en) 2020-09-23
US20160031972A1 (en) 2016-02-04
JP2016516400A (ja) 2016-06-09
CN105722856A (zh) 2016-06-29
AU2014231357A1 (en) 2015-10-22
CA2906960C (en) 2021-07-20
CN105722856B (zh) 2019-04-16
EP2975052A1 (en) 2016-01-20
EP2975052A4 (en) 2017-04-05
JP6462599B2 (ja) 2019-01-30
WO2014139476A1 (zh) 2014-09-18
AU2014231357B2 (en) 2018-06-14
US9856313B2 (en) 2018-01-02
CA2906960A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
WO2014139476A8 (zh) Rsv融合蛋白的表位以及识别其的抗体
EP3308798A3 (en) Polypeptides and antibodies for treating hbv infection and related diseases
WO2015179691A3 (en) Cell penetrating peptides and methods of making and using thereof
WO2015063611A3 (en) Albumin variants and uses thereof
JP2013172734A5 (zh)
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
WO2015061416A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
RU2018132044A (ru) Антитела против тау
CL2015001314A1 (es) Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14).
WO2016071376A3 (en) Fc-region variants with modified fcrn-binding and methods of use
WO2013184976A3 (en) Compositions and methods for antigen-specific tolerance
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
EP3363458A3 (en) A peptide
WO2014136064A3 (en) Immunogenic fusion polypeptides
WO2013098755A3 (en) Anticancer fusion protein
MX2015016627A (es) Vacuna para la malaria.
MX2013007872A (es) Proteina de fusion anticancer.
WO2013150309A8 (en) Clostridium difficile antigens
WO2016161415A3 (en) Tnfrsf14/ hvem proteins and methods of use thereof
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
WO2014144621A3 (en) Modified fc fusion proteins
NZ724133A (en) Tfpi inhibitors and methods of use
WO2011123858A3 (en) Ccn3 peptides and analogs thereof for therapeutic use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14765573

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2015561931

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2906960

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14777275

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2014765573

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014231357

Country of ref document: AU

Date of ref document: 20140317

Kind code of ref document: A